Becton, Dickinson and Co. (BD) reported good news Thursday, as it saw quarterly revenues of $4.784 billion for its fourth fiscal quarter, an increase of 4.4% over the prior-year period. Of note, the company’s life sciences segment saw worldwide revenues of $1.488 billion, representing an increase of 31.2% over the prior-year period as reported, or 31.4% on a currency-neutral basis.

Royal Philips NV is reporting the launch of Philips Ventilator Bipap A40 EFL, a noninvasive ventilator that aims to help patients with chronic obstructive pulmonary disease (COPD) breathe easier. With its CE mark in hand, the company has tagged initial target markets as France, Italy and the U.K. Additional European markets are expected to come next year.

Boston Scientific Corp. has scooped up an approval from the U.S. FDA for the Ranger drug-coated balloon to help those with peripheral artery disease in the superficial femoral artery and proximal popliteal artery.

Boston Scientific Corp. raked in sales of $2.659 billion during the third quarter, a decline of 1.8% on a reported basis vs. the prior year period.

Virtual Incision Corp. revealed that it had received a green light from the U.S. FDA to begin its study of its miniaturized in vivo robotic assistant (MIRA) Platform. Initially, the company will focus the platform on minimally invasive laparoscopic colon surgery. With the MIRA Platform, the company will aim to enter a growing market in the U.S., where more than 400,000 colon resection procedures are performed each year.

Day Zero Diagnostics Inc. has reported that data presented at IDWeek highlighted the promise of the company’s new class of diagnostics as it works toward its goal of detecting superbug infections quickly. The company ultimately is hoping to get regulatory signoffs in both the U.S. and Europe for its technology.